<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMLEXANOX</span><br/>(am-lex'a-nox)<br/><span class="topboxtradename">Aphthasol, </span><span class="topboxtradename">OraDisc A<br/></span><b>Classifications:</b> <span class="classification">skin and mucous membrane agent</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5% paste; 2 mg mucoadhesive disc </p>
<h1><a name="action">Actions</a></h1>
<p>Mechanism of action by which healing of aphthous ulcers occurs is unknown.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Amlexanox reduces healing time and pain related to aphthous ulcers or canker sores.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of aphthous ulcers in patients with normal immune systems.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Sensitivity to amlexanox.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B), lactation. Safety and efficacy in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Aphthous Ulcers</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Topical</span> Apply <small>1/4</small> in. (0.5 cm) to finger and dab onto each mouth ulcer q.i.d. (after oral hygiene p.c. and h.s.) for
               10 d cycle; apply disc to each mouth ulcer and allow to dissolve<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply after oral hygiene following each meal and before bedtime.</li>
<li>Avoid prolonged contact with skin and wash off skin if contact occurs.</li>
<li>Store at 15°30° C (59°86° F) away from heat and moisture. Do not freeze.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Transient pain, stinging, or burning at application site. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Minimally absorbed through ulcer. <span class="typehead">Onset:</span> Approximately 3 d. <span class="typehead">Elimination:</span> 17% of orally absorbed dose excreted in urine. <span class="typehead">Half-Life:</span> 3.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Discontinue use if rash or inflamed membranes develop.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use at first sign of canker sore. Wash hands before and immediately after application.</li>
<li>Flush eyes immediately with large amount of cold water if paste accidentally comes in contact with eyes or eye area.</li>
<li>Contact physician if healing does not result after 10 d of therapy.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>